'PhRMA and the biopharmaceutical research companies we represent are focused on the critical issues that matter to the American people. We can help deliver the solutions that are needed to get COVID-19 under control, bring the economy back and make health care more affordable,' said
Sequeira has served as President of
'Over the past year, the public has witnessed first-hand, the benefits of innovative science as our industry quickly and safely worked together to address one of the greatest health care challenges of our time,' said Sequeira. 'Yet, there continues to be opportunity to improve public perception of our industry. I look forward to working with my colleagues and stakeholders across the health care system to continue advocating for policies that put patients first and foster public trust in science and our industry - especially among communities who continue to feel the disparities and inequities of our health care system.'
Narasimhan joined Novartis in 2005. Prior to serving as CEO, he held a number of leadership roles, including Global Head of Development for Novartis Vaccines and Global Head of Drug Development and Chief Medical Officer. His work at the company includes leading efforts to develop and distribute a vaccine during the 2009 H1N1 pandemic. Narasimhan is an elected member of the
'After what has been the largest and fastest mobilization of global scientific capabilities against a public health crisis, the pandemic is a reminder of the importance of the biopharmaceutical industry and the need to address longstanding health disparities. Taking a collaborative approach, we are eager to work with leaders across government to find solutions that lower what patients pay out-of-pocket and fuel transformative biomedical innovation,' said Narasimhan.
About PhRMA
The
Contact:
Tel: (202) 835-3400
Web: www.PhRMA.org
(C) 2021 Electronic News Publishing, source